Fund moves
90 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 27, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 9, 2026 · Filed Feb 9, 2026
Merck's Chief Marketing Officer sold $1.18M of Merck shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,184,101
Shares × reported transaction price
6 days after results of Feb 3, 2026, 80 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $117.65 on Feb 9, 2026, within 4% of its 52-week high, after an 11% rise over the previous 30 trading days
52-week range $73.47 (May 14, 2025) to $121.93 (Feb 6, 2026), 91% of the way up, from 251 adjusted closes. 30 trading days earlier: $106.45 on Dec 24, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Keytruda on Feb 10, 2026, 1 day after this trade.
New use approved (efficacy supplement). Active ingredient: Pembrolizumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.8% | −1.3% | +5.1% |
| 30 days | −1.1% | −3.8% | +2.7% |
| 90 days | −5.0% | +6.8% | −11.8% |
| 180 days | +11.8% | +11.7% | +0.1% |
Past results only. Not a forecast.
Fund moves
90 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 27, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
8 tracked managers disclosed the same change for Q3 2025. From a 13F filed Feb 17, 2026 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
90 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 17, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.